A single blinded randomized controlled trial assessing the effect of photobiomodulation therapy on neuron specific biomarkers in type II diabetes mellitus patients with peripheral neuropathy
M. Anju , Saleena Ummer Velladath , G. Arun Maiya , Manjunath Hande
{"title":"A single blinded randomized controlled trial assessing the effect of photobiomodulation therapy on neuron specific biomarkers in type II diabetes mellitus patients with peripheral neuropathy","authors":"M. Anju , Saleena Ummer Velladath , G. Arun Maiya , Manjunath Hande","doi":"10.1016/j.diabres.2025.112087","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Diabetic peripheral neuropathy is one of the most devastating complications of long-term diabetes mellitus, associated with functional limitations and poor quality of life.</div></div><div><h3>Materials and methods</h3><div>Two hundred subjects were randomized into intervention and control group, with one hundred in each arm. The intervention arm received photobiomodulation therapy for ten days, with Low −Level Helium-Neon Laser at a wavelength of 632.8 nm of dosage 3.1 J/cm<sup>2</sup> for 9 min on both the dorsal and plantar surfaces of the foot, while the control group received sham laser. Patients were assessed at day 0 of treatment and four weeks after treatment for all the clinical and neuropathy-specific biomarkers. Serum levels of Neuron specific enolase (NSE), Calcitonin gene related peptide (CGRP) Nerve Growth Factor (NGF) for monitoring neuronal changes and monofilament test, Biothesiometer, Numeric Pain Rating Scale (NPRS) to analyze vibration sensation, and pain score. The neuropathic quality of life was assessed using the Norfolk Quality of Life Questionnaire- Diabetic Neuropathy (Norfolk QOL-DN).</div></div><div><h3>Result</h3><div>Trial found significant changes in serum NSE (p < 0.001), CGRP(p < 0.001), MNSI(p < 0.001), VPT(p < 0.001), NPRS(p < 0.001), and NQL(p < 0.001) in the intervention group four weeks after receiving photobiomodulation therapy, whereas no changes in NGF levels(p = 0.937). This was in correlation with improved neuropathic pain and quality of life.</div></div><div><h3>Conclusion</h3><div>Serum levels of NSE and CGRP may be good indicators of effectiveness of photobiomodulation in reducing neuropathic pain and other symptoms in individuals with DPN. Reduced neuropathic symptoms, improved protective sensation of foot and quality of life, and reduced neuropathic pain was observed in intervention group.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112087"},"PeriodicalIF":6.1000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725001019","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Diabetic peripheral neuropathy is one of the most devastating complications of long-term diabetes mellitus, associated with functional limitations and poor quality of life.
Materials and methods
Two hundred subjects were randomized into intervention and control group, with one hundred in each arm. The intervention arm received photobiomodulation therapy for ten days, with Low −Level Helium-Neon Laser at a wavelength of 632.8 nm of dosage 3.1 J/cm2 for 9 min on both the dorsal and plantar surfaces of the foot, while the control group received sham laser. Patients were assessed at day 0 of treatment and four weeks after treatment for all the clinical and neuropathy-specific biomarkers. Serum levels of Neuron specific enolase (NSE), Calcitonin gene related peptide (CGRP) Nerve Growth Factor (NGF) for monitoring neuronal changes and monofilament test, Biothesiometer, Numeric Pain Rating Scale (NPRS) to analyze vibration sensation, and pain score. The neuropathic quality of life was assessed using the Norfolk Quality of Life Questionnaire- Diabetic Neuropathy (Norfolk QOL-DN).
Result
Trial found significant changes in serum NSE (p < 0.001), CGRP(p < 0.001), MNSI(p < 0.001), VPT(p < 0.001), NPRS(p < 0.001), and NQL(p < 0.001) in the intervention group four weeks after receiving photobiomodulation therapy, whereas no changes in NGF levels(p = 0.937). This was in correlation with improved neuropathic pain and quality of life.
Conclusion
Serum levels of NSE and CGRP may be good indicators of effectiveness of photobiomodulation in reducing neuropathic pain and other symptoms in individuals with DPN. Reduced neuropathic symptoms, improved protective sensation of foot and quality of life, and reduced neuropathic pain was observed in intervention group.
期刊介绍:
Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.